LM-302 plus oral S-1 and intraperitoneal paclitaxel, with or without cadonilimab, for Claudin 18.2–positive advanced stomach or GEJ cancer with peritoneal spread

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, exploratory phase 2 interventional trial enrolling adults with HER2-negative, Claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma and confirmed peritoneal metastases. Participants receive LM-302 combined with oral S-1 and intraperitoneal paclitaxel, and some participants also receive cadonilimab. Key eligibility includes Claudin 18.2 expression ≥25% (moderate to strong), ECOG performance status ≤1, and adequate organ function, with peritoneal disease confirmed by laparoscopy. The study will monitor safety, tolerability, and preliminary anti-tumor activity in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed gastric or gastroesophageal junction adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;
* Age ≥ 18 years at registration;
* Peritoneal metastases from gastric cancer requiring definitive diagnosisby laparoscopy, and without gastric outflow tract obstruction andintestinal obstruction;
* Claudin 18.2 positive (≥ 25%, moderate to strong staining);
* Eastern Cooperative Oncology Group (ECOG) score ≤ 1;
* Expected life expectancy \> 3 months;
* Adequate bone marrow, liver, and renal functions.

Exclusion Criteria:

* Presence of distant metastases other than peritoneal metastasis at the time of enrollment;
* Pregnant or breastfeeding women;
* Prior treatment with Claudin 18.2 targeted therapy;
* History of other malignancies within the past 5 years, except for cured skin cancer or cervical carcinoma in situ;
* History of uncontrolled epilepsy, central nervous system disease, or mental disorder that, in the investigator's judgment, may interfere with signing informed consent or compliance with oral medication.
* Clinically significant active heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or higher congestive heart failure, severe arrhythmia requiring medication, or myocardial infarction within the past 12 months;
* Upper gastrointestinal obstruction, abnormal physiological function, or malabsorption syndrome that may affect S 1 absorption;
* Known peripheral neuropathy ≥ NCI CTC AE grade 1. However, patients with loss of deep tendon reflexes (DTR) alone may be included;
* Organ transplantation requiring immunosuppressive therapy;
* Severe uncontrolled recurrent infection or other severe uncontrolled concomitant diseases;
* Moderate or severe renal impairment (creatinine clearance ≤ 50 ml/min) or serum creatinine above the upper limit of normal;
* Known dihydropyrimidine dehydrogenase (DPD) deficiency;
* Active hepatitis (for hepatitis B: HBsAg positive and HBV DNA ≥ 500 IU/ml; for hepatitis C: HCV antibody positive and HCV viral load \> upper limit of normal);
* Psychiatric disorder that makes the patient unable to comply with treatment;
* Allergy to paclitaxel or any component of the study drugs;
* History or evidence of any disease, condition, treatment, or laboratory abnormality that could interfere with the study results or the patient's full participation, or any other condition that, in the investigator's opinion, makes the patient unsuitable for enrollment.

Where it's running

• Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  Shanghai, Huangpu District, China Recruiting

Study contacts

• Study coordinator: Zhongyin Yang
• Email: jeffreyyong@163.com
• Phone: 8621-64370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for advanced gastric cancer with peritoneal metastasis using a combination of therapies

  This study is testing a new combination of treatments for people with advanced gastric cancer that has spread to the abdomen to see if it can help slow down the disease and improve their health.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Huangpu District · NCT06519591

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer

  This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).

  Recruiting Phase 3 Akeso · Phoenix, Arizona and 24 other locations · NCT07700979

• Cadonilimab with chemotherapy for gastric or GEJ cancer

  This trial tests whether adding cadonilimab to standard chemotherapy is safe and effective for adults with locally advanced or resectable gastric or GEJ cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07631000

• Cadonilimab plus high-dose interferon in neoadjuvant treatment for stage III/IV melanoma

  This trial tests whether giving cadonilimab with high-dose interferon before surgery can shrink tumors in people with stage III or resectable stage IV melanoma and whether it is safe.

  Recruiting Early Phase 1 Xijing Hospital · Xi'an · NCT07586904

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.